Pirfenidone for the Treatment of Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis (PF/IPF)

• Adverse events, clinical lab tests, directed physical exams [ Time Frame: Assessments are at 6 month intervals up to approximately 8 years ] [ Designated as safety issue: Yes ]
• FVC, DLco,resting SpO2, oxygen utilization, acute IPF exacerbations, survival time [ Time Frame: Assessments are at 6 month intervals up to approximately 8 years ] [ Designated as safety issue: No ]

• - Oxygen utilization
• Safety Outcome Measures:
• - Adverse events
• - Clinical laboratory tests
• - Directed physical examinations, including vital signs
• Efficacy Outcome Measures:
• - Forced vital capacity (FVC)
• - Carbon monoxide diffusing capacity (DLco)
• - Resting SpO2 assessed by pulsed oximetry
• - Acute IPF exacerbations
• - Survival time

To assess the long-term safety and efficacy of oral pirfenidone in doses of up to 40 mg/kg/d in a limited number of patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF)

This study has been designed as a rollover study to collectively include safety and efficacy data from various previous studies.

In addition, InterMune has also initiated an Early Access Program to make pirfenidone available to a limited number of patients with idiopathic pulmonary fibrosis in the United States. This program is also being conducted under this protocol. Registration of patients with documented IPF has been closed as of October 2005.

• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

General Inclusion Criteria:

• Able to understand and sign an informed consent form;
• Understand the importance of adherence to study treatment and the study protocol, including concomitant medication restrictions, throughout the study period;
• Patients must be willing to travel to an approved regional center for all study-related visits

Roll-Over Criteria:

• Entry into study through rollover has been completed

Criteria for Early Access Program patients:

• Clinical symptoms consistent with IPF ≥3 months duration;
• Age 40 - 85, inclusive;
• At the time of registration with NORD, patients with IPF must have a percent predicted FVC of ≥50%, and percent predicted DLCO of ≥35%
• At the time of enrollment in PIPF-002, (screening/baseline visit) percent predicted FVC must be ≥45%, and percent predicted DLCO must be ≥30%
• High-resolution computed tomographic scan (HRCT) showing definite IPF. For patients with surgical lung biopsy showing definite or probable usual interstitial pneumonia (UIP), the HRCT criterion of probable IPF is sufficient;
• For patients aged <50 years: open or video-assisted thoracoscopic (VATS) lung biopsy showing definite or probable UIP.In addition, no features supporting an alternative diagnosis on transbronchial biopsy or bronchoalveolar lavage if performed.
• For patients aged ≥50 years: at least one of the following diagnostic findings as well as the absence of any features on specimens resulting from any of these procedures that support an alternative diagnosis:
• Open or VATS lung biopsy showing definite or probable UIP
• Transbronchial biopsy showing no features to support an alternative diagnosis
• Bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis.